Genprex (GNPX) Competitors $0.70 -0.02 (-3.44%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends GNPX vs. CDIO, DRRX, LVTX, ENLV, MRKR, ATHE, LPCN, GDTC, FBRX, and BCABShould you be buying Genprex stock or one of its competitors? The main competitors of Genprex include Cardio Diagnostics (CDIO), DURECT (DRRX), LAVA Therapeutics (LVTX), Enlivex Therapeutics (ENLV), Marker Therapeutics (MRKR), Alterity Therapeutics (ATHE), Lipocine (LPCN), CytoMed Therapeutics (GDTC), Forte Biosciences (FBRX), and BioAtla (BCAB). These companies are all part of the "pharmaceutical products" industry. Genprex vs. Cardio Diagnostics DURECT LAVA Therapeutics Enlivex Therapeutics Marker Therapeutics Alterity Therapeutics Lipocine CytoMed Therapeutics Forte Biosciences BioAtla Genprex (NASDAQ:GNPX) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends. Is GNPX or CDIO more profitable? Genprex has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -22,732.03%. Cardio Diagnostics' return on equity of -258.85% beat Genprex's return on equity.Company Net Margins Return on Equity Return on Assets GenprexN/A -409.48% -269.17% Cardio Diagnostics -22,732.03%-258.85%-191.20% Which has higher valuation & earnings, GNPX or CDIO? Cardio Diagnostics has higher revenue and earnings than Genprex. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenprexN/AN/A-$30.86MN/AN/ACardio Diagnostics$20K1,229.38-$8.38MN/AN/A Do institutionals and insiders believe in GNPX or CDIO? 14.1% of Genprex shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 8.5% of Genprex shares are owned by insiders. Comparatively, 22.3% of Cardio Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community favor GNPX or CDIO? Genprex received 195 more outperform votes than Cardio Diagnostics when rated by MarketBeat users. However, 80.00% of users gave Cardio Diagnostics an outperform vote while only 65.25% of users gave Genprex an outperform vote. CompanyUnderperformOutperformGenprexOutperform Votes19965.25% Underperform Votes10634.75% Cardio DiagnosticsOutperform Votes480.00% Underperform Votes120.00% Which has more volatility and risk, GNPX or CDIO? Genprex has a beta of -1.3, indicating that its share price is 230% less volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 3.76, indicating that its share price is 276% more volatile than the S&P 500. Do analysts rate GNPX or CDIO? Genprex currently has a consensus target price of $10.00, indicating a potential upside of 1,338.43%. Cardio Diagnostics has a consensus target price of $2.00, indicating a potential upside of 228.95%. Given Genprex's higher possible upside, analysts plainly believe Genprex is more favorable than Cardio Diagnostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cardio Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor GNPX or CDIO? In the previous week, Genprex had 1 more articles in the media than Cardio Diagnostics. MarketBeat recorded 1 mentions for Genprex and 0 mentions for Cardio Diagnostics. Genprex's average media sentiment score of 0.00 equaled Cardio Diagnostics'average media sentiment score. Company Overall Sentiment Genprex Neutral Cardio Diagnostics Neutral SummaryCardio Diagnostics beats Genprex on 7 of the 12 factors compared between the two stocks. Get Genprex News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGenprexPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.92M$6.58B$5.39B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E RatioN/A10.0188.8317.53Price / SalesN/A335.371,284.8780.48Price / CashN/A22.6336.6032.90Price / Book0.145.084.964.69Net Income-$30.86M$154.90M$117.89M$224.57M7 Day Performance-5.80%2.59%2.75%3.33%1 Month Performance-23.60%1.52%3.63%5.33%1 Year Performance-91.68%5.50%27.26%22.98% Genprex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGenprex4.2526 of 5 stars$0.70-3.4%$10.00+1,338.4%-91.4%$6.13MN/A0.0020Positive NewsCDIOCardio Diagnostics2.5035 of 5 stars$0.62-7.6%$2.00+222.6%-76.1%$25.07M$35,688.000.007Gap DownDRRXDURECT4.0563 of 5 stars$0.80+4.0%$5.00+523.6%+16.1%$24.89M$8.59M-1.3180Positive NewsLVTXLAVA Therapeutics3.2001 of 5 stars$0.98+0.2%$3.33+241.1%-40.9%$24.78M$7.35M-0.9560Positive NewsENLVEnlivex Therapeutics3.3171 of 5 stars$1.16+0.9%$9.50+721.9%-58.8%$24.74MN/A-1.1870Gap UpMRKRMarker Therapeutics4.1313 of 5 stars$2.75-2.8%$19.00+590.9%-43.1%$24.54M$3.31M0.0060News CoverageGap UpATHEAlterity Therapeutics2.1516 of 5 stars$3.34flat$6.00+79.6%+83.9%$24.40MN/A0.0010Short Interest ↑LPCNLipocine1.9789 of 5 stars$4.55-7.0%$10.00+119.8%+15.9%$24.33M$7.92M-5.9910News CoverageGDTCCytoMed Therapeutics1.6511 of 5 stars$2.22-19.6%$5.00+125.2%-39.0%$24.29MN/A0.00N/APositive NewsGap UpFBRXForte Biosciences3.3798 of 5 stars$16.50-7.2%$23.58+42.9%+55,870.1%$24.12MN/A-1.015Analyst ForecastNews CoverageBCABBioAtla2.5763 of 5 stars$0.50-6.2%$6.00+1,102.6%-75.1%$24.12M$11M-0.2960Short Interest ↑ Related Companies and Tools Related Companies CDIO Competitors DRRX Competitors LVTX Competitors ENLV Competitors MRKR Competitors ATHE Competitors LPCN Competitors GDTC Competitors FBRX Competitors BCAB Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNPX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genprex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genprex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
